CRI Ops™ — Compliance Recovery Intelligence

The Scenario

The countdown. Novulytix — a synthetic medtech & diagnostics manufacturer organized into three divisions: Cardia Rhythm Solutions (Waukegan, IL — implantable cardiac devices), Pharma Manufacturing (Munich, DE — consumable potency products), and Scientific Systems (Marlborough, MA — connected diagnostics) — is under an FDA Warning Letter, escalated from a Form 483 that cited an inadequately addressed repeated complaint trend and CAPA effectiveness gaps. The committed FDA response milestone is 15 business days out. A newly appointed Chief Quality Officer inherits open commitments, conflicting status reports, and a board asking two simple questions: what is actually happening across our operation — and which actions matter most right now?

The hero case fires — CRI-2026-0483, Warning Letter Operational Reality Assessment (Critical). The pressure queue surfaces five active cases; the hero is the one with the tightest milestone. CRI conducts a Rapid Understanding Engagement — agent-assisted operational discovery across six source systems (MES, CAPA, Complaints/MDR, Supplier Quality (SCARs), LIMS, and Regulatory Commitments) plus management decks and consultant trackers — matching each artifact to the case by division, system, product line, and semantic similarity, and running structured interviews derived from Novulytix’s own SOPs and quality manual, the governing regulations and standards, and the historical CAPA, audit, complaint, and deviation records.

What the operational reality reveals:

• CAPA effectiveness is asserted, not proven. CAPA-NS-2025-118 was closed on training-completion criteria — outcome effectiveness data is missing (GAP-01). The Q1 management review deck reports CAPA effectiveness as green/on-track; the underlying evidence reads amber.
• Recurrence crosses divisions and systems. A seal-integrity nonconformance recurred from Cardia Rhythm Solutions’ Waukegan Line 2 to Line 4 (MES), correlates with an accessory complaint cluster in Scientific Systems (Marlborough, Complaints/MDR), and a supplier SCAR pattern — three closed on supplier “commitment” with no incoming-verification evidence (GAP-03). A Pharma Manufacturing (Munich) LIMS potency out-of-trend is the early signal of a fourth recurrence. Isolated QMS review treated each in isolation; CRI connects them into one evidence trail.
• Spend isn’t moving risk. Three consultant streams consume 41% of remediation spend for ~19% risk reduction — flagged for descope. The consultant tracker marks tasks “complete” with no attached source artifacts (GAP-02) — undefendable to an inspector until evidence is attached.

Ten-stage governed engagement. The active response advances through Pressure Signal Intake, Standards & Requirement Mapping, Operational Discovery, Stakeholder Interviews, Evidence Collection, Contradiction Detection, Root Cause Identification, Recovery Roadmap Generation, Executive Review, and Long-Term Prevention Planning. Each stage runs a CRI agent trace, then pauses for a required human reviewer — CQO, Regulatory, Legal, Site Quality, or CAPA Owner — before anything is accepted. Agents do the structured legwork; human experts stay in the loop at every stage, especially discovery and interviews.

The Recovery Roadmap — the Top Five Actions. Rather than dumping 127 findings, CRI converges on the few moves that actually reduce risk before the milestone, each scored by P×I×C and evidence strength, with an owner and a date. Open gaps are disclosed up front — not discovered by the inspector.

Evidence is the product, captured under your control. Every record carries a certainty tier (Fact ~98% · Derived ~87% · Hypothesis ~65% · Conjecture ~50%), a confidence level, a risk impact, an actionability class (Safe · Review · Escalate), full provenance (source system → source ID → site → owner), and an included / excluded state. Discovery and evidence stay inside the customer environment; retention, redaction, and legal review are customer-controlled — no uncontrolled or permanent memory.

The aha: you learned more about this operation in two days than a consulting team learned in six weeks — and you know exactly what to do next.

The Problem

Status decks instead of operational reality. Under FDA pressure, the truth lives in status decks, consultant trackers, and self-reported “on-track” — not in source-linked evidence. CAPA effectiveness is reported green because training was completed, while the outcome data that would actually defend it is missing. When the inspector asks prove it, the team reconstructs from fragments.

Understanding takes too long. A traditional bench of 20 consultants spends six weeks building a picture of what is happening — and still produces a 100-finding report that buries the few actions that matter. By the time the diagnosis lands, the milestone is closer and the recovery hasn’t started. Consultants are necessary but limited; the bottleneck is structured discovery, not headcount.

Recurrence hidden by silos. Each QMS workflow sees its own slice. The deviation system sees a seal-integrity nonconformance. The complaint system sees an accessory adverse-event cluster. Supplier quality sees a SCAR. Nobody connects them — so the same failure mode recurs across lines, sites, and product families, and the Warning Letter response addresses symptoms instead of the systemic cause.

Who This Is For

Chief Quality Officers, VP Quality and compliance leaders, CEOs/COOs, CFOs, boards and risk committees, and general counsel in medical device and pharmaceutical manufacturing facing FDA enforcement — 483s, Warning Letters, consent-decree risk — who need to understand, fast and with evidence, what is actually happening and which actions matter most before the next milestone.

How CRI Is Positioned

CRI is phased. Lead with Phase 1.

• Phase 1 — Understand reality. A 2–4 week Rapid Understanding Engagement: agent-assisted discovery produces an Operational Reality Assessment and the Recovery Roadmap’s Top Five Actions.
• Phase 2 — Accelerate recovery. Drive the roadmap to closure with evidence-backed, human-approved actions.
• Phase 3 — Prevent recurrence. Long-term prevention planning so the same failure mode doesn’t return.
• Phase 4 — Cognitive Operations. A broader operating layer over time — never the opening pitch.

What You’ll Experience

• Pressure Queue — active FDA-pressure cases for Novulytix, prioritized by severity and milestone pressure, starting with the hero Warning Letter operational-reality assessment.
• Operational Reality — an evidence-backed read on what is actually happening across ten signals, each drilling into its source records or an explicit gap, with management-reported green flagged where the evidence reads amber.
• 10-Stage Active Response — a governed Rapid Understanding Engagement with a CRI agent trace and a required human-approval gate at every stage, preserved in an immutable audit trail.
• Operational Reality Intelligence — operational-reality, CAPA-effectiveness, and evidence-defensibility trends with management-vs-evidence variance the board can act on.
• Agent-Assisted Operational Discovery — structured interviews and cross-site pattern detection that connect fragmented MES, CAPA, complaint, supplier, and LIMS records into a single recurrence trail isolated review misses — with experts in the loop.
• Customer-Controlled Knowledge Capture — every CRI recommendation carries certainty, confidence, actionability, provenance, and a human-approval requirement; discovery stays inside your environment, and CRI never files a response, closes a CAPA, or changes an SOP autonomously.
• CRI Copilot — scripted, deterministic answers that show reasoning stages, cited evidence, confidence, certainty, actionability, and the approval requirement for every response.
• Evidence & Context — a source-linked evidence register with provenance, certainty, and included/excluded package state, plus a transparent missing-evidence queue.
• Remediation Actions — the Recovery Roadmap’s Top Five Actions, prioritized by risk reduction, deadline, evidence strength, and owner feasibility, with P×I×C scoring and a spend-to-risk view for the CFO.
• Board Reporting — an independent operational reality for the CFO and board, including where management-reported green diverges from the evidence, with spend-to-risk movement.
• Inspector Package — a defensible, evidence-backed response preview where gaps are disclosed, not hidden, and nothing is filed without human approval.
• Collateral Browser & Document Comparison — every source document behind the response plus the full Novulytix Quality System library (SOPs, quality manual, and historical CAPA, audit, complaint, and deviation records, alongside the regulatory standards and product reference library) — filterable by library, viewable with element-level source citations that deep-link to the exact clause, and set side by side in traditional-vs-CRI comparisons with a verdict on each row.
• Resource Center — the FDA pressure ladder, the 483 anatomy model, the CRI method and its three pillars, and the governance boundaries that keep every recommendation safe and reviewable.